Sympathetic inhibition with methyldopa in heart failure
| Autor: | Jack Juni, Philip C. Kirlin, Bertram Pitt, Charles B. Smith, Roger Grekin, Sunil K. Das, Robert J. Weiss, Milton D. Gross |
|---|---|
| Rok vydání: | 1986 |
| Předmět: |
Adult
Male medicine.medical_specialty Sympathetic Nervous System Physical exercise Plasma renin activity Sympatholytic Internal medicine medicine Humans Methyldopa Aged Pharmacology Heart Failure Ejection fraction business.industry Neural Inhibition Middle Aged medicine.disease Endocrinology medicine.anatomical_structure Heart failure Vascular resistance Catecholamine Female Cardiology and Cardiovascular Medicine business medicine.drug |
| Zdroj: | Journal of cardiovascular pharmacology. 8(5) |
| ISSN: | 0160-2446 |
| Popis: | The hypothesis that withdrawal of increased sympathetic activity may be beneficial in heart failure was tested by administration of the centrally acting adrenergic inhibitor methyldopa. Fourteen subjects with chronic, stable New York Heart Association Functional Class 2 or 3 heart failure receiving digitalis and diuretics were randomized to methyldopa (n = 8) 500-1000 mg daily or placebo (n = 6). Clinical, hemodynamic, neurohumoral, and platelet alpha 2-receptor effects were studied after chronic (3 weeks) administration. Sympathetic inhibition did not alter symptom status or exercise duration but reduced plasma norepinephrine concentration during exercise and permitted the same level of exercise to be attained at a lower pressure-rate product, indicating reduced myocardial oxygen consumption. Left ventricular ejection fraction and stroke volume tended to increase, and systemic vascular resistance tended to decrease during exercise after methyldopa administration, suggesting enhanced vasodilation. Upright plasma renin activity increased from 8.2 +/- 2.2 to 13.3 +/- 3.0 ng/nl/h (p = 0.03) after methyldopa, but plasma antidiuretic hormone concentration changed insignificantly. In a subset of patients, platelet alpha 2-receptor density and affinity were unaltered. Renal function was also unchanged. Thus, sympathetic inhibition induced by methyldopa in selected patients with chronic, stable heart failure does not worsen symptom status or exercise performance, and may produce a beneficial effect by withdrawal of excess sympathetic activity with reduction of plasma norepinephrine levels. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|